Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B

PHASE4UnknownINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Chronic Hepatitis B
Interventions
DRUG

Pegasys plus Entecavir

Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks

DRUG

Entecavir

ETV 0.5 mg daily monotherapy for 144 weeks

Trial Locations (1)

100

RECRUITING

National Taiwan University Hospital Department of Internal medicine, Taipei

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

National Taiwan University Hospital

OTHER

NCT00597259 - Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B | Biotech Hunter | Biotech Hunter